ImmunoCellular Therapeutics, Ltd' ICT-107 Recognized As One of Windhover’s Top 10 Most Licensable Oncology Products

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular" or the "Company") (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that ICT-107 was recognized as one of Windhover’s Top 10 licensable oncology products. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries. ICT-107 is the Company’s lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.